Under construction – not a live service
Sign in
Taking people in EgyptPhase 2

Tests radiation therapy delivered in fewer, boosted doses for prostate cancer

Tests a boosted radiation schedule in adults with high-risk prostate cancer.

Plain-language title generated from the registry record
Registry title: Efficacy and Safety of Simultaneous Integrated Boost Radiotherapy in HR/VHR Prostate Cancer With EPLNI

Key facts

Where
Cairo, Shibīn al Kawm, and Sohag, EgyptSee the 3 sites
Phase
Phase 2

Where in Egypt

  • Faculty of Medicine-Ain Shams UniversityCairo, EgyptTaking people
  • Faculty of Medicine - Menoufia UniversityShibīn al Kawm, EgyptTaking people
  • Faculty of Medicine, Sohag UniversitySohag, EgyptTaking people

Questions to ask the study team

  1. How often do I need to come in, and for how long each time?
  2. Are travel costs paid?
  3. Can I keep my own doctor?
  4. What happens if I want to stop?
Print a page for my doctor

Trial details

Who runs it
Ain Shams University
Trial code
NCT07693075
Record updated
9 July 2026
Original description
The aim of this study is to evaluate the efficacy and safety of hypofractionated simultaneous integrated boost volumetric arc radiation therapy (SIB - VMAT) for high-risk and very high-risk localized prostate cancer in terms of:Read full original descriptionShow less

Prospective Evaluation of Efficacy and Safety of Simultaneous Integrated Boost (SIB-VMAT) Radiotherapy in HR/VHR Prostate Cancer With EPLNI

The aim of this study is to evaluate the efficacy and safety of hypofractionated simultaneous integrated boost volumetric arc radiation therapy (SIB - VMAT) for high-risk and very high-risk localized prostate cancer in terms of:

1. Acute and late gastrointestinal and genitourinary toxicities. 2. Evaluate the efficacy in terms of early bPFS. 3. Dosimetric evaluation in terms of target coverage and organs at risk sparing

Inclusion: Histologically confirmed adenocarcinoma of the prostate; Classification as High-Risk (HR) or Very High-Risk (VHR) per NCCN guidelines (e.g., T3a+, PSA > 20 ng/mL, or Gleason Score 8-10); Adequate baseline urinary function (IPSS \le 20); Multiparametric MRI of the prostate; CT Chest, Abdomen, and Pelvis; Bone scan; Optional: PSMA-PET/CT to definitively exclude distant metastases (M1) and provide high-fidelity nodal assessment prior to treatment planning.

Exclusion: Prior pelvic radiotherapy; History of Inflammatory Bowel Disease (IBD) or active severe proctitis; Presence of distant metastases.

ClinicalTrials.gov NCT07693075